Superseded · version 2: MOTS-c^↗

Related names recorded in this version: MOTS-C^↗

A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.^↗↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.

Update · July 29, 2026

We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review. ²³

What this version reported

FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.^↗↗

Organizations named in cited records:

U.S. Food and Drug Administration^↗↗↗

Sources for this version

1
Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
2
FDA briefing document for MOTS-c ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
3
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026